Aktionsplan Cogent Biosciences, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
Биофармацевтическая компания Unum Therapeutics Inc. специализируется на разработке ряда новых методов лечения онкологических больных. Новая запатентованная технология компании, известная как Bolt-On Chimeric Receptor (BOXR), разработана для улучшения функциональности сконструированных Т-клеток путем обнаружения и включения трансгена «болт-на» в сконструированные Т-клетки пациента для преодоления резистентности микроокружение солидной опухоли для атаки Т-клеток.
Weitere Details| P/S | 0.9658 |
|---|---|
| EV/EBITDA | 0.3129 |
| EBITDA | -0.0309 |
| Цена ао | 11.6 |
| Сайт | http://www.cogentbio.com |
| P/BV | 0.6841 |
| Число акций ао | 0.07966 млрд |
| ISIN | US19240Q2012 |
| Выручка | 0.0225 |
| Валюта | usd |
| IPO date | 2018-03-29 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Preisänderung pro Tag: | +1.44% (11.09) |
|---|---|
| Preisänderung pro Woche: | +1.26% (11.11) |
| Preisänderung pro Monat: | +9.54% (10.27) |
| Preisänderung über 3 Monate: | +21.62% (9.25) |
| Preisänderung über sechs Monate: | +74.15% (6.46) |
| Preisänderung pro Jahr: | +19.62% (9.405) |
| Preisänderung über 3 Jahre: | +22.55% (9.18) |
| Preisänderung über 5 Jahre: | +546.55% (1.74) |
| Preisänderung seit Jahresbeginn: | +40.98% (7.98) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Blackrock Inc. | 6755584 | 7.07 |
| Kynam Capital Management, LP | 5854766 | 6.12 |
| Tcg Crossover Management, Llc | 5631042 | 5.89 |
| COMMODORE CAPITAL LP | 5566026 | 5.82 |
| FMR, LLC | 5302854 | 5.55 |
| Point72 Asset Management, L.P. | 5191448 | 5.43 |
| VR Adviser, LLC | 4684167 | 4.9 |
| Vanguard Group Inc | 4534655 | 4.74 |
| State Street Corporation | 4150615 | 4.34 |
| Suvretta Capital Management, LLC | 3710539 | 3.88 |
| ETF | Aktie, % | Rentabilität für das Jahr, % | Dividenden, % |
|---|---|---|---|
| iShares ESG Aware MSCI USA Small-Cap ETF | 0.05316 | 31.110458284371 | 1.49366 |
| iShares Morningstar Small-Cap ETF | 0.01798 | 30.095066471445 | 1.60498 |
| iShares Morningstar Small-Cap Growth ETF | 0.02305 | 33.628071953382 | 0.72598 |
| iShares Morningstar Small Cap Value ETF | 0.01318 | 26.701717953559 | 2.50476 |
| iShares Micro-Cap ETF | 0.25553 | 34.327031588619 | 1.54048 |
| iShares Russell 2000 Growth ETF | 0.06937 | 38.042556988 | 0.6026 |
| iShares Russell 3000 ETF | 0.00184 | 31.230028873917 | 1.43482 |
| iShares Morningstar Small-Cap ETF | 0.01798 | 391.25300933451 | 1.60498 |
| iShares Morningstar Small-Cap Growth ETF | 0.02305 | 682.83677107207 | 0.72598 |
| iShares Morningstar Small-Cap Value ETF | 0.01318 | 226.82308420057 | 2.50476 |
| Principal Healthcare Innovators ETF | 0.1166 | 618.4964157054 | 0.8416 |
| Future Tech ETF | 0.1166 | 426.33969118983 | 0.8416 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Andrew R. Robbins M.B.A. | President, CEO & Director | 1.06M | 1976 (48 Jahre) |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer | 763.99k | 1980 (44 Jahr) |
| Dr. Jessica Sachs M.D. | Chief Medical Officer | 773.92k | 1975 (49 Jahre) |
| Mr. Brad Barnett | Chief Technology Officer | N/A | |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer | 749.89k | 1975 (49 Jahre) |
| Ms. Erin Schellhammer | Chief People Officer | N/A | |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary | N/A | 1980 (44 Jahr) |
| Mr. Dana R. Martin Pharm.D. | Senior VP of Medical Affairs & Chief Patient Officer | N/A | |
| Brad Fell | Senior Vice President of Chemistry | N/A | |
| Ms. Christi Waarich | Senior Director of Investor Relations |
Adresse: United States, Cambridge, MA , 200 Cambridge Park Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: http://www.cogentbio.com
Webseite: http://www.cogentbio.com
